| First Author | Duffen J | Year | 2018 |
| Journal | J Immunol | Volume | 200 |
| Issue | 4 | Pages | 1347-1359 |
| PubMed ID | 29305434 | Mgi Jnum | J:257624 |
| Mgi Id | MGI:6116014 | Doi | 10.4049/jimmunol.1701256 |
| Citation | Duffen J, et al. (2018) Modulation of the IL-33/IL-13 Axis in Obesity by IL-13Ralpha2. J Immunol 200(4):1347-1359 |
| abstractText | In obesity, IL-13 overcomes insulin resistance by promoting anti-inflammatory macrophage differentiation in adipose tissue. Endogenous IL-13 levels can be modulated by the IL-13 decoy receptor, IL-13Ralpha2, which inactivates and depletes the cytokine. In this study, we show that IL-13Ralpha2 is markedly elevated in adipose tissues of obese mice. Mice deficient in IL-13Ralpha2 had high expression of IL-13 response markers in adipose tissue, consistent with increased IL-13 activity at baseline. Moreover, exposure to the type 2 cytokine-inducing alarmin, IL-33, enhanced serum and tissue IL-13 concentrations and elevated tissue eosinophils, macrophages, and type 2 innate lymphoid cells. IL-33 also reduced body weight, fat mass, and fasting blood glucose levels. Strikingly, however, the IL-33-induced protection was greater in IL-13Ralpha2-deficient mice compared with wild-type littermates, and these changes were largely attenuated in mice lacking IL-13. Although IL-33 administration improved the metabolic profile in the context of a high fat diet, it also resulted in diarrhea and perianal irritation, which was enhanced in the IL-13Ralpha2-deficient mice. Weight loss in this group was associated with reduced food intake, which was likely related to the gastrointestinal effects. These findings outline both potentially advantageous and deleterious effects of a type 2-skewed immune response under conditions of metabolic stress, and identify IL-13Ralpha2 as a critical checkpoint in adipose tissues that limits the protective effects of the IL-33/IL-13 axis in obesity. |
